Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-07-01 |
Uniqure (The Netherlands) |
$ 20 million (€ 14.6 million) |
loan |
Hercules Technology Growth Capital (USA) |
Rare diseases - Genetic diseases |
Loan |
2014-07-01 |
Celyad previously known as Cardio3 Biosciences (Belgium) |
€25 million |
capital increase |
Medisun International Limited (China) |
Cardiovascular diseases |
Capital increase |
2014-07-01 |
Karo Bio (Sweden) |
SEK 3.8 million (€0.4 million) |
grant |
Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) |
Cancer - Oncology |
Grant |
2014-06-30 |
Ablynx (Belgium) |
€41.7 million |
private placement |
domestic and international institutional investors |
Cancer - Oncology - Hematological diseases - Inflammatory diseases - Lung diseases |
Private placement |
2014-06-24 |
Zealand Pharma (Denmark) |
DKK 1 million (€0.13 million) |
grant |
Danish Innovation Fund (InnovationsFonden) (Denmark) |
Metabolic diseases |
Grant |
2014-06-24 |
Fab’entech (France) |
€5 million |
fundraising |
Auriga Partners (France), R2V (France), Rhône-Alpes Création (France), Sigma Gestion (France) and several companies investing on a personal level. |
Infectious diseases |
Fundraising |
2014-06-23 |
Genfit (France) |
€49.7 million |
private placement |
|
Metabolic diseases - Liver diseases - Inflammatory diseases |
Private placement |
2014-06-23 |
Dimension Therapeutics (USA - MA) |
$30 million |
financing round |
OrbiMed (USA - NY) Fidelity Biosciences (USA - MA) |
Rare diseases |
Financing round |
2014-06-19 |
Innate Pharma (France) |
€50 million |
capital increase |
specialist institutional investors |
Cancer - Oncology - Inflammatory diseases |
Capital increase |
2014-06-18 |
Ziarco (UK) |
£1.7m (€2.1 million) |
grant |
Technology Strategy Board (UK) |
Dermatological diseases - Immunological diseases - Inflammatory diseases |
Grant |
2014-06-17 |
Pixium Vision (France) |
€34.5 million |
IPO |
French and international institutional investors, French retail investors, Bpifrance Participations (France), Sofinnova (France), Abingworth (UK), Omnes Capital (France), Innobio (France) Seventure (France) |
Ophtalmological diseases |
IPO |
2014-06-17 |
Cantargia (Sweden) |
20 MSEK |
private placement of new shares |
|
Cancer - Oncology |
Private placement |
2014-06-16 |
Oxford BioMedica (UK) |
£21.6 million |
fundraising |
|
Ophtalmalogical diseases - Genetic diseases - Rare diseases |
Fundraising |
2014-06-14 |
Horizon Discovery (UK) LGC (UK) |
£360,224 (€449887,5) |
grant |
Technology Strategy Board (UK) |
Technology - Services |
Grant |
2014-06-12 |
Integragen (France) |
€4.6 million |
capital increase |
|
Cancer - Oncology - CNS diseases |
Capital increase |
2014-06-10 |
to-BBB (The Netherlands) |
€10 million |
series C financing round |
new and existing investors |
CNS diseases - Neurodegenerative diseases - Cancer - Oncology - Neuroinflammatory diseases |
Series C financing round |
2014-06-06 |
Nordic Nanovector (Norway) |
NOK 250 million (€30.7 million) |
private placement |
existing shareholders |
Cancer - Oncology |
Private placement |
2014-06-06 |
Trianta Immunotherapies, a Medigene subsidiary (Germany) |
€380 000 |
grant |
Federal Ministry of Education and Research (BMBF) (Germany) |
Cancer - Oncology - Autoimmune diseases |
Grant |
2014-06-04 |
Agalimmune (UK-USA) |
undisclosed |
|
Loxbridge Research (UK), Animatrix Capital (UK) |
Cancer - Oncology |
Milestone |
2014-06-04 |
Autifony Therapeutics (UK) |
£2.2 million (€2.7 million) |
grant |
Technology Strategy Board (UK) |
Otorhinolaryngology |
Grant |